A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	B-protein
receptor	I-protein
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
and	O
expression	O
of	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	B-cell_type
leukocytes	I-cell_type
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B-protein
molecules	I-protein
for	O
leukocytes	B-cell_type
[	O
e.g.	O
,	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ELAM-1	B-protein
)	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ICAM-1	B-protein
)	O
]	O
.	O

We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
for	O
neutrophils	B-cell_type
(	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
)	O
.	O

Preincubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram/ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O

Moreover	O
,	O
the	O
steroid	B-protein
receptor	I-protein
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	B-protein
receptors	I-protein
[	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
hGRs	B-protein
)	O
]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O

RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	B-protein
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	B-protein
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	B-cell_type
cells	I-cell_type
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O

Treatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	B-protein
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	B-protein
ELAM-1	I-protein
and	O
ICAM-1	B-protein
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O

Dexamethasone	O
markedly	O
inhibited	O
LPS-stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	B-protein
and	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4-9	O
)	O
;	O
inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4-6	O
)	O
.	O

As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	B-protein
molecules	I-protein
.	O

These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	B-protein
-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	B-protein
receptor	I-protein
is	O
a	O
hormone-dependent	O
regulator	O
of	O
transcription	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

89	NULL
,	NULL
pp	NULL
.	NULL

9991-9995	NULL
,	NULL
November	NULL
1992	NULL
Medical	NULL
Sciences	NULL
A	NULL
mechanism	NULL
for	NULL
the	NULL
antiinflammatory	NULL
effects	NULL
of	NULL
corticosteroids	NULL
:	NULL
The	NULL
glucocorticoid	NULL
receptor	NULL
regulates	NULL
leukocyte	NULL
adhesion	NULL
to	NULL
endothelial	NULL
cells	NULL
and	NULL
expression	NULL
of	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
and	NULL
intercellular	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
neutrophils	NULL
/endothelium	NULL
/	NULL
inflammation	NULL
)	NULL
BRUCE	NULL
N.	NULL
CRONSTEIN®*	NULL
,	NULL
STEVEN	NULL
C	NULL
.	NULL

KimmEL	NULL
?	NULL

,	NULL
RicHARD	NULL
I	NULL
;	NULL
LEvIN	NULL
,	NULL
FRANK	NULL
MARTINIUK	NULL
,	NULL
AND	NULL
GERALD	NULL
WEISSMANN	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Divisions	NULL
of	NULL
Rheumatology	NULL
and	NULL
Cardiology	NULL
,	NULL
New	NULL
York	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
550	NULL
First	NULL
Avenue	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10016	NULL
Communicated	NULL
by	NULL
H.	NULL
Sherwood	NULL
Lawrence	NULL
,	NULL
June	NULL
17	NULL
,	NULL
1992	NULL
(	NULL
received	NULL
for	NULL
review	NULL
December	NULL
9	NULL
,	NULL
1991	NULL
)	NULL
ABSTRACT	NULL
Corticosteroids	NULL
are	NULL
the	NULL
preeminent	NULL
antiinflammatory	NULL
agents	NULL
although	NULL
the	NULL
molecular	NULL
mechanisms	NULL
that	NULL
impart	NULL
their	NULL
efficacy	NULL
have	NULL
not	NULL
been	NULL
defined	NULL
.	NULL

The	NULL
endothelium	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
inflammation	NULL
by	NULL
directing	NULL
circulating	NULL
leukocytes	NULL
into	NULL
extravascular	NULL
tissues	NULL
by	NULL
expressing	NULL
adhesive	NULL
molecules	NULL
for	NULL
leukocytes	NULL
[	NULL
e.g	NULL
.	NULL

,	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ELAM-1	NULL
)	NULL
and	NULL
intercellular	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ICAM-1	NULL
)	NULL
]	NULL
.	NULL

We	NULL
therefore	NULL
determined	NULL
whether	NULL
corticosteroids	NULL
suppress	NULL
inflammation	NULL
by	NULL
inhibiting	NULL
endothelial	NULL
expression	NULL
of	NULL
adhesion	NULL
molecules	NULL
for	NULL
neutrophils	NULL
(	NULL
polymorphonuciear	NULL
leuko-cytes	NULL
)	NULL
.	NULL

Preincubation	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
endotoxin	NULL
[	NULL
lipo-polysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
,	NULL
1	NULL
pg/ml	NULL
)	NULL
led	NULL
to	NULL
a	NULL
4-fold	NULL
increase	NULL
in	NULL
subsequent	NULL
adherence	NULL
of	NULL
polymorphonuclear	NULL
leukocytes	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
,	NULL
z	NULL
=	NULL
10	NULL
)	NULL
to	NULL
endothelial	NULL
cells	NULL
,	NULL
an	NULL
increase	NULL
that	NULL
was	NULL
markedly	NULL
attenuated	NULL
when	NULL
endothelial	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
dexamethasone	NULL
(	NULL
ICs	NULL
,	NULL
<	NULL
1	NULL
nM	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
,	NULL
n	NULL
=	NULL
6	NULL
or	NULL
7	NULL
)	NULL
during	NULL
preincubation	NULL
with	NULL
LPS	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
steroid	NULL
receptor	NULL
agonist	NULL
cortisol	NULL
(	NULL
10	NULL
LM	NULL
)	NULL
,	NULL
but	NULL
not	NULL
its	NULL
inactive	NULL
metabolite	NULL
tetrahydrocortisol	NULL
(	NULL
10	NULL
M	NULL
)	NULL
,	NULL
diminished	NULL
LPS-induced	NULL
endothelial	NULL
cell	NULL
adhesiveness	NULL
.	NULL

Further	NULL
evidence	NULL
that	NULL
the	NULL
action	NULL
of	NULL
dexamethasone	NULL
was	NULL
mediated	NULL
through	NULL
ligation	NULL
of	NULL
corticosteroid	NULL
receptors	NULL
{	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
hGRs	NULL
)	NULL
]	NULL
was	NULL
provided	NULL
by	NULL
experiments	NULL
utilizing	NULL
the	NULL
steroid	NULL
antagonist	NULL
RU-486	NULL
.	NULL

RU-486	NULL
(	NULL
10	NULL
4M	NULL
)	NULL
,	NULL
which	NULL
prevents	NULL
translocation	NULL
of	NULL
ligated	NULL
hGR	NULL
to	NULL
the	NULL
nucleus	NULL
by	NULL
inhibiting	NULL
dissociation	NULL
of	NULL
hGR	NULL
from	NULL
heat	NULL
shock	NULL
protein	NULL
90	NULL
,	NULL
completely	NULL
aborted	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
adhesiveness	NULL
of	NULL
endothelial	NULL
cells	NULL
(	NULL
P	NULL
<	NULL
0.0005	NULL
,	NULL
»	NULL
=	NULL
3	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
LPS	NULL
(	NULL
1	NULL
pg/ml	NULL
!	NULL
)	NULL

stimulated	NULL
transcription	NULL
of	NULL
ELAM-1	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
membrane-associated	NULL
ELAM-1	NULL
and	NULL
ICAM-1	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
quantitative	NULL
immunofluorescence	NULL
(	NULL
both	NULL
P	NULL
<	NULL
0.001	NULL
,	NULL
r	NULL
=	NULL
9	NULL
)	NULL
.	NULL

Dexamethasone	NULL
markedly	NULL
inhibited	NULL
LPS-stimulated	NULL
accumulation	NULL
of	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
and	NULL
expression	NULL
of	NULL
ELAM-1	NULL
and	NULL
ICAM-1	NULL
(	NULL
ICs	NULL
,	NULL
<	NULL
10	NULL
nM	NULL
,	NULL
both	NULL
P	NULL
?	NULL

<	NULL
0.001	NULL
,	NULL
»	NULL
=	NULL
4-9	NULL
)	NULL
;	NULL
inhibition	NULL
of	NULL
expression	NULL
by	NULL
dexamethasone	NULL
was	NULL
reversed	NULL
by	NULL
RU-486	NULL
(	NULL
both	NULL
P	NULL
<	NULL
0.005	NULL
,	NULL
n	NULL
=	NULL
4-6	NULL
)	NULL
.	NULL

As	NULL
in	NULL
the	NULL
adhesion	NULL
studies	NULL
,	NULL
cortisol	NULL
but	NULL
not	NULL
tetrahydrocortisol	NULL
inhibited	NULL
expression	NULL
of	NULL
EL	NULL
AM-1	NULL
and	NULL
ICAM-1	NULL
(	NULL
both	NULL
P	NULL
<	NULL
0.005	NULL
,	NULL
r	NULL
=	NULL
3	NULL
or	NULL
4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
sodium	NULL
salicylate	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
inhibited	NULL
neither	NULL
adhesion	NULL
nor	NULL
expression	NULL
of	NULL
these	NULL
adhesion	NULL
molecules	NULL
.	NULL

These	NULL
studies	NULL
suggest	NULL
that	NULL
antagonism	NULL
by	NULL
dexamethasone	NULL
of	NULL
endotoxin-induced	NULL
inflammation	NULL
is	NULL
a	NULL
specific	NULL
instance	NULL
of	NULL
the	NULL
general	NULL
biological	NULL
principle	NULL
that	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
is	NULL
a	NULL
hormone-dependent	NULL
regulator	NULL
of	NULL
transcription	NULL
.	NULL

Although	NULL
glucocorticoids	NULL
are	NULL
among	NULL
the	NULL
most	NULL
potent	NULL
and	NULL
widely	NULL
used	NULL
antiinflammatory	NULL
agents	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
they	NULL
reduce	NULL
inflammation	NULL
are	NULL
unknown	NULL
.	NULL

Various	NULL
hy	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

potheses	NULL
have	NULL
been	NULL
proposed	NULL
;	NULL
these	NULL
include	NULL
'	NULL
``	NULL
'allosteric	NULL
``	NULL
effects	NULL
on	NULL
enzymes	NULL
(	NULL
1	NULL
)	NULL
,	NULL
redirection	NULL
of	NULL
lymphocyte	NULL
traffic	NULL
(	NULL
2	NULL
)	NULL
,	NULL
direct	NULL
inhibition	NULL
of	NULL
various	NULL
phospholipases	NULL
(	NULL
3	NULL
)	NULL
,	NULL
induction	NULL
of	NULL
such	NULL
proteins	NULL
as	NULL
lipocortin	NULL
(	NULL
4	NULL
)	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
transcription	NULL
of	NULL
various	NULL
cytokines	NULL
and	NULL
metalloproteases	NULL
(	NULL
5-14	NULL
)	NULL
,	NULL
and	NULL
our	NULL
own	NULL
earlier	NULL
suggestion	NULL
that	NULL
glucocorticoids	NULL
stabilize	NULL
lysoso-mal	NULL
and	NULL
other	NULL
cellular	NULL
membranes	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

However	NULL
,	NULL
none	NULL
of	NULL
these	NULL
hypotheses	NULL
is	NULL
sufficient	NULL
to	NULL
account	NULL
for	NULL
the	NULL
well-known	NULL
pharmacologic	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
humans	NULL
:	NULL
leuko-cytosis	NULL
(	NULL
17	NULL
)	NULL
,	NULL
inhibition	NULL
of	NULL
leukocyte	NULL
recruitment	NULL
to	NULL
inflamed	NULL
areas	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
,	NULL
retention	NULL
of	NULL
lymphocytes	NULL
in	NULL
the	NULL
lymphatic	NULL
circulation	NULL
with	NULL
shrinkage	NULL
of	NULL
peripheral	NULL
lymph	NULL
nodes	NULL
,	NULL
and	NULL
the	NULL
promotion	NULL
of	NULL
microbial	NULL
infection	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
endothelial	NULL
cells	NULL
can	NULL
direct	NULL
the	NULL
traffic	NULL
of	NULL
leukocytes	NULL
into	NULL
inflamed	NULL
and	NULL
infected	NULL
areas	NULL
(	NULL
heterotypic	NULL
adhesion	NULL
)	NULL
via	NULL
the	NULL
regulated	NULL
expression	NULL
of	NULL
surface	NULL
adhesive	NULL
molecules	NULL
[	NULL
e.g	NULL
.	NULL

,	NULL
GMP140	NULL
,	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ELAM-1	NULL
)	NULL
,	NULL
intercellular	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ICAM-1	NULL
)	NULL
,	NULL
and	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
(	NULL
VCAM	NULL
)	NULL
(	NULL
20-23	NULL
)	NULL
]	NULL
.	NULL

In	NULL
a	NULL
complementary	NULL
fashion	NULL
,	NULL
leukocytes	NULL
also	NULL
express	NULL
proteins	NULL
[	NULL
CD11a-c/CD18	NULL
,	NULL
L-selec-tin	NULL
,	NULL
or	NULL
lectin/epidermal	NULL
growth	NULL
factor	NULL
cell	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
LECAM-1	NULL
)	NULL
]	NULL
on	NULL
their	NULL
surface	NULL
that	NULL
mediate	NULL
their	NULL
specific	NULL
localization	NULL
to	NULL
sites	NULL
of	NULL
inflammation	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Agents	NULL
that	NULL
modulate	NULL
the	NULL
interaction	NULL
of	NULL
leukocytes	NULL
with	NULL
the	NULL
endothelium	NULL
may	NULL
,	NULL
therefore	NULL
,	NULL
possess	NULL
potent	NULL
antiinflammatory	NULL
properties	NULL
.	NULL

We	NULL
now	NULL
present	NULL
data	NULL
compatible	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
glucocorticoids-at	NULL
nanomolar	NULL
concentrations-inhibit	NULL
the	NULL
expression	NULL
of	NULL
adhesive	NULL
molecules	NULL
ELAM-1	NULL
and	NULL
ICAM-1	NULL
by	NULL
endotoxin-activated	NULL
endothelial	NULL
cells	NULL
and	NULL
thereby	NULL
interfere	NULL
with	NULL
the	NULL
traffic	NULL
of	NULL
leukocytes	NULL
into	NULL
inflamed	NULL
areas	NULL
.	NULL

Pretreatment	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
corticosteroids	NULL
prevents	NULL
endothelial	NULL
cells	NULL
from	NULL
becoming	NULL
more	NULL
adhesive	NULL
for	NULL
neutrophils	NULL
[	NULL
polymor-phonuclear	NULL
leukocytes	NULL
(	NULL
PMNs	NULL
)	NULL
]	NULL
and	NULL
diminishes	NULL
stimulated	NULL
expression	NULL
of	NULL
ICAM-1	NULL
and	NULL
ELAM-1	NULL
,	NULL
molecules	NULL
critical	NULL
for	NULL
neutrophil	NULL
adhesion	NULL
.	NULL

Moreover	NULL
,	NULL
these	NULL
data	NULL
make	NULL
it	NULL
likely	NULL
that	NULL
corticosteroids	NULL
regulate	NULL
ELAM-1	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
.	NULL

Lipopolysaccharide	NULL
(	NULL
LPS	NULL
,	NULL
Salmonella	NULL
typhimu-rium	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Calbiochem	NULL
and	NULL
N-formylmethio-nylleucyiphenylalanine	NULL
was	NULL
obtained	NULL
from	NULL
Vega	NULL
Biochemi-	NULL
Abbreviations	NULL
:	NULL
ELAM-1	NULL
,	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
;	NULL
ICAM-1	NULL
,	NULL
intercellular	NULL
adhesion	NULL
molecule	NULL
1	NULL
;	NULL
PMN	NULL
,	NULL
polymorphonuclear	NULL
leukocyte	NULL
;	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
;	NULL
HUVEC	NULL
,	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cell	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
hGR	NULL
,	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

*Present	NULL
address	NULL
:	NULL
7421	NULL
North	NULL
University	NULL
Drive	NULL
,	NULL
Suite	NULL
207	NULL
,	NULL
Tamarac	NULL
,	NULL
FL	NULL
33321	NULL
.	NULL

9992	NULL
Medical	NULL
Sciences	NULL
:	NULL
Cronstein	NULL
et	NULL
al	NULL
.	NULL

cal	NULL
.	NULL

Collagenase	NULL
,	NULL
dexamethasone	NULL
,	NULL
hydrocortisone	NULL
,	NULL
tetrahydrocortisol	NULL
,	NULL
and	NULL
sodium	NULL
salicylate	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

RU-486	NULL
was	NULL
a	NULL
gift	NULL
to	NULL
Herbert	NULL
Samuels	NULL
(	NULL
Roussel-Uclaf	NULL
)	NULL
.	NULL

Medium	NULL
199	NULL
,	NULL
RPMI	NULL
1640	NULL
,	NULL
and	NULL
fetal	NULL
bovine	NULL
serum	NULL
were	NULL
obtained	NULL
from	NULL
GIBCO	NULL
.	NULL

Ficoll	NULL
/Hypaque	NULL
was	NULL
purchased	NULL
from	NULL
Nyegaard	NULL
(	NULL
Oslo	NULL
)	NULL
.	NULL

All	NULL
other	NULL
salts	NULL
and	NULL
reagents	NULL
were	NULL
of	NULL
the	NULL
highest	NULL
quality	NULL
that	NULL
could	NULL
be	NULL
obtained	NULL
.	NULL

Monoclonal	NULL
Antibodies	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
the	NULL
monoclonal	NULL
antibodies	NULL
used	NULL
included	NULL
antibodies	NULL
directed	NULL
against	NULL
ICAM-1	NULL
(	NULL
84H10	NULL
,	NULL
AMAC	NULL
,	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
ELAM-1	NULL
(	NULL
BMA	NULL
4D10	NULL
,	NULL
Accurate	NULL
Chemicals	NULL
,	NULL
Westbury	NULL
,	NULL
NY	NULL
,	NULL
and	NULL
H18/7	NULL
,	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Michael	NULL
Bevilacqua	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
,	NULL
MOPC21	NULL
,	NULL
and	NULL
UPC10	NULL
,	NULL
nonbinding	NULL
isotype	NULL
controls	NULL
.	NULL

Fluorescein-labeled	NULL
anti-IgG	NULL
,	NULL
goat	NULL
anti-mouse	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
GAM-FITC	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Coulter	NULL
Immunology	NULL
.	NULL

Endothelial	NULL
cells	NULL
were	NULL
also	NULL
stained	NULL
with	NULL
rhodamine-labeled	NULL
Ulex	NULL
europaeus	NULL
agglutinin	NULL
I	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
;	NULL
all	NULL
monoclonal	NULL
antibody	NULL
studies	NULL
were	NULL
performed	NULL
in	NULL
ice-cold	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
with	NULL
0.02	NULL
%	NULL
sodium	NULL
azide	NULL
and	NULL
0.025	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
.	NULL

Culture	NULL
of	NULL
Endothelial	NULL
Cells	NULL
.	NULL

Human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
(	NULL
HUVECs	NULL
)	NULL
were	NULL
cultured	NULL
as	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
performed	NULL
on	NULL
endothelial	NULL
cells	NULL
in	NULL
their	NULL
third	NULL
passage	NULL
.	NULL

Incubation	NULL
of	NULL
Endothelial	NULL
Cells	NULL
with	NULL
Pharmacologic	NULL
Agents	NULL
.	NULL

Endothelial	NULL
cells	NULL
were	NULL
stimulated	NULL
by	NULL
incubation	NULL
with	NULL
LPS	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
in	NULL
a	NULL
medium	NULL
consisting	NULL
of	NULL
RPMI	NULL
1640/10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
for	NULL
4	NULL
hr	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
with	NULL
or	NULL
without	NULL
other	NULL
agents	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
monolayers	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
.	NULL

PMN	NULL
Adhkerence	NULL
to	NULL
Endothelial	NULL
Monolayers	NULL
(	NULL
Heterotypic	NULL
Adherence	NULL
)	NULL
.	NULL

PMNs	NULL
(	NULL
150,000	NULL
per	NULL
well	NULL
)	NULL
,	NULL
isolated	NULL
from	NULL
whole	NULL
blood	NULL
as	NULL
described	NULL
(	NULL
27	NULL
)	NULL
,	NULL
suspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
were	NULL
added	NULL
to	NULL
monolayers	NULL
of	NULL
endothelial	NULL
cells	NULL
and	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
and	NULL
adherence	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
unstimulated	NULL
HUVECs	NULL
with	NULL
each	NULL
of	NULL
the	NULL
agents	NULL
used	NULL
did	NULL
not	NULL
affect	NULL
basal	NULL
PMN	NULL
adherence	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
highest	NULL
concentration	NULL
of	NULL
diluent	NULL
used	NULL
(	NULL
ethanol	NULL
,	NULL
0.1	NULL
%	NULL
)	NULL
also	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
PMN	NULL
adherence	NULL
to	NULL
LPS-stimulated	NULL
endothelium	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
PMNs	NULL
were	NULL
labeled	NULL
with	NULL
``	NULL
In	NULL
and	NULL
after	NULL
incubation	NULL
of	NULL
labeled	NULL
PMNs	NULL
with	NULL
endothelium	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
adherence	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
previously	NULL
described	NULL
method	NULL
(	NULL
29	NULL
)	NULL
and	NULL
expressed	NULL
as	NULL
%	NULL
adherence	NULL
.	NULL

Expression	NULL
of	NULL
ELAM-1	NULL
and	NULL
ICAM-1	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
4	NULL
hr	NULL
with	NULL
various	NULL
stimuli	NULL
and	NULL
agents	NULL
the	NULL
HUVECs	NULL
were	NULL
removed	NULL
from	NULL
wells	NULL
by	NULL
exposure	NULL
to	NULL
EDTA	NULL
(	NULL
0.01	NULL
%	NULL
,	NULL
wt/vol	NULL
)	NULL
in	NULL
PBS	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
followed	NULL
by	NULL
gentle	NULL
scraping	NULL
with	NULL
a	NULL
rubber	NULL
policeman	NULL
and	NULL
trituration	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
in	NULL
ice-cold	NULL
saline	NULL
containing	NULL
sodium	NULL
azide	NULL
(	NULL
0.02	NULL
%	NULL
)	NULL
and	NULL
saturating	NULL
concentrations	NULL
of	NULL
antibodies	NULL
,	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
and	NULL
counterstained	NULL
with	NULL
fluorescein-labeled	NULL
anti-IgG	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
fixed	NULL
in	NULL
formaldehyde	NULL
(	NULL
3.7	NULL
%	NULL
in	NULL
PBS	NULL
)	NULL
.	NULL

HUVECs	NULL
were	NULL
then	NULL
analyzed	NULL
with	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
the	NULL
fluorescence	NULL
of	NULL
cells	NULL
stained	NULL
with	NULL
an	NULL
isotype	NULL
control	NULL
antibody	NULL
(	NULL
MOPC21	NULL
)	NULL
was	NULL
33	NULL
+	NULL
13	NULL
.	NULL

Analysis	NULL
of	NULL
Message	NULL
for	NULL
ELAM-1	NULL
.	NULL

HUVECs	NULL
were	NULL
incubated	NULL
without	NULL
or	NULL
with	NULL
stimuli	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
for	NULL
3	NULL
hr	NULL
at	NULL
37°C	NULL
.	NULL

Following	NULL
treatment	NULL
with	NULL
collagenase	NULL
[	NULL
0.1	NULL
%	NULL
/0.01	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
]	NULL
celis	NULL
were	NULL
suspended	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
mRNA	NULL
was	NULL
isolated	NULL
by	NULL
use	NULL
of	NULL
the	NULL
FastTrack	NULL
kit	NULL
following	NULL
the	NULL
instructions	NULL
provided	NULL
(	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
.	NULL

After	NULL
electrophoresis	NULL
through	NULL
agarose	NULL
the	NULL
mRNA	NULL
was	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
and	NULL
hybridized	NULL
with	NULL
full-length	NULL
*	NULL
>	NULL
P-labeled	NULL
cDNA	NULL
probes	NULL
for	NULL
ELAM-1	NULL
(	NULL
generously	NULL
supplied	NULL
by	NULL
Tucker	NULL
Collins	NULL
)	NULL
and	NULL
actin	NULL
(	NULL
Stratagene	NULL
)	NULL
under	NULL
conditions	NULL
of	NULL
high	NULL
stringency	NULL
.	NULL

Labeled	NULL
cDNA	NULL
for	NULL
ELAM-1	NULL
hybridized	NULL
with	NULL
a	NULL
single	NULL
band	NULL
of	NULL
3.65	NULL
kilobases	NULL
(	NULL
kb	NULL
)	NULL
and	NULL
labeled	NULL
cDNA	NULL
for	NULL
actin	NULL
hybridized	NULL
with	NULL
a	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
single	NULL
band	NULL
of	NULL
2.0	NULL
kb	NULL
.	NULL

Autoradiograms	NULL
were	NULL
prepared	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
laser	NULL
densitometry	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Statistical	NULL
Analysis	NULL
.	NULL

The	NULL
significance	NULL
of	NULL
differences	NULL
among	NULL
and	NULL
between	NULL
experimental	NULL
treatment	NULL
groups	NULL
was	NULL
determined	NULL
by	NULL
means	NULL
of	NULL
the	NULL
appropriate	NULL
level	NULL
of	NULL
analysis	NULL
of	NULL
variance	NULL
and	NULL
determination	NULL
of	NULL
separate	NULL
post-hoc	NULL
variances	NULL
by	NULL
means	NULL
of	NULL
the	NULL
CSS	NULL
Software	NULL
(	NULL
Statsoft	NULL
,	NULL
Tulsa	NULL
,	NULL
OK	NULL
)	NULL
using	NULL
an	NULL
IBM-compat-ible	NULL
computer	NULL
.	NULL

RESULTS	NULL
Glucocorticoids	NULL
Prevent	NULL
Adhesion	NULL
of	NULL
PMNs	NULL
to	NULL
LPS-Stimulated	NULL
Endothelial	NULL
Cells	NULL
(	NULL
Heterotypic	NULL
Adhesion	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
HUVECs	NULL
with	NULL
LPS	NULL
or	NULL
cytokines	NULL
[	NULL
interleukin	NULL
1	NULL
(	NULL
IL-1	NULL
)	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
TNF-a	NULL
)	NULL
]	NULL
causes	NULL
endothelial	NULL
cells	NULL
to	NULL
bind	NULL
unstimulated	NULL
PMNs	NULL
more	NULL
avidly	NULL
(	NULL
20	NULL
,	NULL
21	NULL
,	NULL
30	NULL
,	NULL
32	NULL
)	NULL
.	NULL

When	NULL
we	NULL
treated	NULL
HUVECs	NULL
with	NULL
LPS	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
we	NULL
found	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
that	NULL
~4-fold	NULL
more	NULL
PMNs	NULL
adhered	NULL
to	NULL
treated	NULL
than	NULL
untreated	NULL
HUVECs	NULL
(	NULL
50	NULL
+	NULL
3	NULL
vs.	NULL
13	NULL
+	NULL
2	NULL
PMNs	NULL
per	NULL
high-power	NULL
field	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

Dexamethasone	NULL
inhibited	NULL
PMN	NULL
adhesion	NULL
to	NULL
the	NULL
LPS-stimulated	NULL
HUVECs	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
ICsp	NULL
<	NULL
1	NULL
nM	NULL
,	NULL
P	NULL
<	NULL
0.005	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Glucocorticoid	NULL
Receptors	NULL
Mediate	NULL
the	NULL
Effects	NULL
of	NULL
Glucocorticoids	NULL
on	NULL
Adhesion	NULL
of	NULL
PMNs	NULL
to	NULL
HUVECs	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
modulation	NULL
of	NULL
endothelial	NULL
adhesiveness	NULL
by	NULL
dexamethasone	NULL
was	NULL
receptor-mediated	NULL
we	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
RU-486	NULL
,	NULL
a	NULL
noncompetitive	NULL
antagonist	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

RU-486	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
completely	NULL
reversed	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
LPS-stimulated	NULL
adhesiveness	NULL
of	NULL
HUVECs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
P	NULL
<	NULL
0.0005	NULL
)	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
100-fold	NULL
higher	NULL
concentrations	NULL
of	NULL
the	NULL
less	NULL
potent	NULL
steroid	NULL
receptor	NULL
agonist	NULL
cortisol	NULL
(	NULL
IC	NULL
,	NULL
=	NULL
100	NULL
nM	NULL
,	NULL
n	NULL
=	NULL
2	NULL
)	NULL
,	NULL
but	NULL
not	NULL
its	NULL
inactive	NULL
metabolite	NULL
tetrahydrocortisol	NULL
(	NULL
0.1	NULL
and	NULL
10	NULL
mM	NULL
)	NULL
,	NULL
diminished	NULL
the	NULL
LPS-stimulated	NULL
increment	NULL
in	NULL
adhesiveness	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
neither	NULL
indomethacin	NULL
(	NULL
10	NULL
M	NULL
)	NULL
nor	NULL
sodium	NULL
salicylate	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
affected	NULL
the	NULL
LPS-stimulated	NULL
increment	NULL
in	NULL
endothelial	NULL
adhesiveness	NULL
.	NULL

Glucocorticoids	NULL
Modulate	NULL
Expression	NULL
of	NULL
ELAM-1	NULL
and	NULL
ICAM-1	NULL
on	NULL
LPS-Stimulated	NULL
Endothelium	NULL
.	NULL

We	NULL
next	NULL
determined	NULL
whether	NULL
the	NULL
effect	NULL
of	NULL
corticosteroids	NULL
on	NULL
endothelial	NULL
cell	NULL
adhesiveness	NULL
resulted	NULL
from	NULL
diminished	NULL
expression	NULL
of	NULL
ELAM-1	NULL
or	NULL
ICAM-1	NULL
.	NULL

After	NULL
stimulation	NULL
by	NULL
LPS	NULL
,	NULL
HUVECs	NULL
increased	NULL
expression	NULL
of	NULL
ELAM-1	NULL
by	NULL
321	NULL
%	NULL
+	NULL
68	NULL
%	NULL
(	NULL
SEM	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
,	NULL
n	NULL
=	NULL
16	NULL
)	NULL
and	NULL
ICAM-1	NULL
by	NULL
250	NULL
%	NULL
+	NULL
38	NULL
%	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
,	NULL
n	NULL
=	NULL
16	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

125	NULL
100	NULL
E	NULL
}	NULL
I	NULL
75	NULL
{	NULL
so	NULL
-	NULL
4+RU-486	NULL
@	NULL
BUFFER	NULL
%	NULL
Maximal	NULL
Adhesion	NULL
25	NULL
t	NULL
y	NULL
i	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
DEXAMETHASONE	NULL
[	NULL
nM	NULL
]	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Inhibition	NULL
by	NULL
dexamethasone	NULL
(	NULL
0.1-1000	NULL
nM	NULL
)	NULL
of	NULL
PMN	NULL
adhesion	NULL
to	NULL
LPS-stimulated	NULL
HUVECs	NULL
.	NULL

HUVECs	NULL
were	NULL
stimulated	NULL
,	NULL
as	NULL
above	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
various	NULL
doses	NULL
of	NULL
dexamethasone	NULL
and	NULL
RU-486	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
.	NULL

Adherence	NULL
of	NULL
PMNs	NULL
to	NULL
unstimulated	NULL
endothelium	NULL
was	NULL
determined	NULL
and	NULL
subtracted	NULL
from	NULL
the	NULL
PMN	NULL
adherence	NULL
to	NULL
stimulated	NULL
endothelium	NULL
and	NULL
then	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
net	NULL
adherence	NULL
of	NULL
PMNs	NULL
to	NULL
untreated	NULL
endothelial	NULL
monolayers	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
RU-486	NULL
did	NULL
not	NULL
affect	NULL
adhesion	NULL
of	NULL
PMNs	NULL
to	NULL
either	NULL
unstimulated	NULL
(	NULL
122	NULL
%	NULL
+	NULL
16	NULL
%	NULL
of	NULL
control	NULL
,	NULL
n	NULL
=	NULL
4	NULL
)	NULL
or	NULL
LPS-treated	NULL
endothelium	NULL
(	NULL
114	NULL
%	NULL
+	NULL
11	NULL
%	NULL
of	NULL
control	NULL
,	NULL
n	NULL
=	NULL
4	NULL
)	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Cronstein	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
9993	NULL
LPS	NULL
(	NULL
1ng/ml	NULL
)	NULL
--	NULL
CONTROL	NULL
--	NULL
--	NULL
200	NULL
ELAM-1	NULL
r—IOAH-i—	NULL
ULEX	NULL
[	NULL
}	NULL
CONTROL	NULL
|	NULL
|	NULL
a	NULL
I	NULL
,	NULL
0	NULL
Z.	NULL
Mou	NULL
aa	NULL
31	NULL
129	NULL
14	NULL
15	NULL
200	NULL
&	NULL
A	NULL
RU-486	NULL
(	NULL
1M	NULL
)	NULL
H	NULL
A	NULL
w	NULL
H	NULL
\	NULL
-	NULL
1	NULL
t	NULL
Mk	NULL
®	NULL
4	NULL
}	NULL
/	NULL
0	NULL
0	NULL
I	NULL
,	NULL
\\	NULL
.	NULL

/	NULL
\	NULL
a	NULL
&	NULL
128	NULL
257	NULL
14	NULL
§	NULL
200	NULL
$	NULL
3	NULL
1	NULL
;	NULL
5	NULL
a	NULL
cm	NULL
bod	NULL
DEXAMETHASONE	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
-	NULL
|	NULL
_	NULL
(	NULL
1	NULL
aA	NULL
f	NULL
///\	NULL
//I	NULL
\	NULL
/	NULL
s	NULL
m_	NULL
OL	NULL
8s	NULL
194	NULL
13	NULL
200	NULL
f	NULL
n	NULL
gt	NULL
t	NULL
1	NULL
RU-486	NULL
+	NULL
DEXAMETHASONE	NULL
H	NULL
~	NULL
p	NULL
H	NULL
1	NULL
\	NULL
/	NULL
/	NULL
-*	NULL
/	NULL
\	NULL
ol-	NULL
Save	NULL
100	NULL
10	NULL
``	NULL
102L	NULL
103	NULL
129	NULL
16	NULL
10	NULL
10	NULL
|103	NULL
10m	NULL
in	NULL
10	NULL
10	NULL
249	NULL
1	NULL
FLUORESCENCE	NULL
(	NULL
RFU	NULL
)	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Inhibition	NULL
by	NULL
dexamethasone	NULL
of	NULL
the	NULL
increased	NULL
surface	NULL
expression	NULL
of	NULL
ICAM-1	NULL
and	NULL
ELAM-1	NULL
by	NULL
LPS-stimulated	NULL
HUVECs	NULL
.	NULL

Fluorescence	NULL
histograms	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
top	NULL
row	NULL
,	NULL
resting	NULL
and	NULL
activated	NULL
(	NULL
LPS	NULL
,	NULL
1	NULL
ug/m	NULL
!	NULL
)	NULL

HUVECs	NULL
stained	NULL
with	NULL
antibodies	NULL
directed	NULL
against	NULL
ICAM-1	NULL
,	NULL
ELAM-1	NULL
,	NULL
and	NULL
Ulex	NULL
europaeus	NULL
agglutinin	NULL
I	NULL
;	NULL
second	NULL
row	NULL
,	NULL
resting	NULL
and	NULL
activated	NULL
HUVECs	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RU-486	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
;	NULL
third	NULL
row	NULL
,	NULL
HUVECs	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
;	NULL
and	NULL
bottom	NULL
row	NULL
,	NULL
resting	NULL
and	NULL
activated	NULL
HUVECs	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
LM	NULL
)	NULL
and	NULL
RU-486	NULL
(	NULL
10	NULL
LM	NULL
)	NULL
.	NULL

Mean	NULL
fluorescence	NULL
of	NULL
cells	NULL
stained	NULL
with	NULL
FITC-labeled	NULL
antibody	NULL
(	NULL
MOPC-21	NULL
)	NULL
alone	NULL
was	NULL
10	NULL
relative	NULL
fluorescence	NULL
units	NULL
(	NULL
RFU	NULL
)	NULL
.	NULL

Shown	NULL
is	NULL
a	NULL
representative	NULL
experiment	NULL
of	NULL
seven	NULL
,	NULL
the	NULL
mean	NULL
results	NULL
of	NULL
which	NULL
are	NULL
presented	NULL
in	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
.	NULL

Dexamethasone	NULL
(	NULL
ICsp	NULL
<	NULL
1	NULL
nM	NULL
)	NULL
inhibited	NULL
the	NULL
LPS-stimulated	NULL
expression	NULL
of	NULL
ELAM-1	NULL
and	NULL
ICAM-1	NULL
(	NULL
P	NULL
<	NULL
0.00001	NULL
and	NULL
P	NULL
<	NULL
0.00001	NULL
,	NULL
respectively	NULL
,	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
without	NULL
altering	NULL
basal	NULL
expression	NULL
of	NULL
these	NULL
molecules	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Dexamethasone	NULL
did	NULL
not	NULL
alter	NULL
binding	NULL
of	NULL
rhodamine-labeled	NULL
Ulex	NULL
europaeus	NULL
agglutinin	NULL
I	NULL
to	NULL
the	NULL
endothelial	NULL
cell	NULL
surface	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
none	NULL
of	NULL
the	NULL
compounds	NULL
studied	NULL
affected	NULL
the	NULL
nonspecific	NULL
binding	NULL
of	NULL
antibodies	NULL
MOPC21	NULL
,	NULL
UPCIO	NULL
(	NULL
isotype	NULL
controls	NULL
)	NULL
,	NULL
or	NULL
FITC	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
RU-486	NULL
completely	NULL
reversed	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
LPS-stimulated	NULL
expression	NULL
of	NULL
ICAM-1	NULL
and	NULL
ELAM-1	NULL
(	NULL
P	NULL
<	NULL
0.004	NULL
,	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

100	NULL
I3	NULL
i	NULL
I	NULL
e1CAM-1	NULL
~~	NULL
80	NULL
-	NULL
I	NULL
mELAM-1	NULL
w	NULL
C	NULL
0	NULL
E	NULL
ha	NULL
5	NULL
60	NULL
<	NULL
0	NULL
hy	NULL
E	NULL
40	NULL
0	NULL
e	NULL
a€	NULL
20	NULL
I	NULL
u	NULL
I	NULL
I	NULL
7	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
[	NULL
Dexamethasone	NULL
]	NULL
(	NULL
nM	NULL
)	NULL
FiG	NULL
.	NULL

3	NULL
.	NULL

Inhibition	NULL
by	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
nM-10	NULL
uM	NULL
)	NULL
of	NULL
the	NULL
up-regulation	NULL
of	NULL
ICAM-1	NULL
and	NULL
ELAM-1	NULL
expression	NULL
on	NULL
LPS-stimulated	NULL
HUVECs	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
4-10	NULL
experiments	NULL
.	NULL

RFU	NULL
,	NULL
relative	NULL
fluorescence	NULL
units	NULL
.	NULL

Although	NULL
RU-486	NULL
appeared	NULL
to	NULL
diminish	NULL
LPS-stimulated	NULL
up-regulation	NULL
of	NULL
ICAM-1	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
the	NULL
difference	NULL
observed	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

Similarly	NULL
,	NULL
cortisol	NULL
,	NULL
but	NULL
neither	NULL
tetrahydrocortisol	NULL
nor	NULL
sodium	NULL
salicylate	NULL
,	NULL
inhibited	NULL
expression	NULL
of	NULL
ICAM-1	NULL
and	NULL
ELAM-1	NULL
(	NULL
P	NULL
<	NULL
0.003	NULL
,	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
agents	NULL
studied	NULL
affected	NULL
binding	NULL
of	NULL
Ulex	NULL
europaeus	NULL
agglutinin	NULL
I	NULL
to	NULL
HUVECs	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Glucocorticoids	NULL
Prevent	NULL
Accumulation	NULL
of	NULL
Message	NULL
for	NULL
ELAM-1	NULL
in	NULL
Response	NULL
to	NULL
LPS	NULL
and	NULL
IL-1a	NULL
But	NULL
Not	NULL
in	NULL
Response	NULL
to	NULL
TNF	NULL
.	NULL

To	NULL
further	NULL
define	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
glucocorticoids	NULL
inhibit	NULL
up-regulation	NULL
of	NULL
adhesive	NULL
molecules	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
on	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
in	NULL
HUVECs	NULL
.	NULL

Treatment	NULL
of	NULL
HUVECs	NULL
with	NULL
LPS	NULL
,	NULL
IL-la	NULL
(	NULL
20	NULL
units/ml	NULL
)	NULL
,	NULL
and	NULL
TNF	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
stimulated	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
detectable	NULL
message	NULL
for	NULL
ELAM-1	NULL
in	NULL
HUVECs	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Dexamethasone	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
did	NULL
not	NULL
affect	NULL
basal	NULL
levels	NULL
of	NULL
mRNA	NULL
for	NULL
EL	NULL
AM-1	NULL
but	NULL
markedly	NULL
inhibited	NULL
the	NULL
LPS-and	NULL
IL-1a-stimulated	NULL
increase	NULL
in	NULL
message	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
dexamethasone	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
TNF-stimulated	NULL
increment	NULL
in	NULL
detectable	NULL
ELAM-1	NULL
message	NULL
,	NULL
an	NULL
observation	NULL
that	NULL
suggests	NULL
that	NULL
glucocorticoids	NULL
do	NULL
not	NULL
directly	NULL
affect	NULL
stability	NULL
of	NULL
message	NULL
for	NULL
ELAM-1	NULL
.	NULL

Although	NULL
these	NULL
findings	NULL
need	NULL
to	NULL
be	NULL
fortified	NULL
by	NULL
further	NULL
studies	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
the	NULL
stability	NULL
of	NULL
ELAM-1	NULL
message	NULL
and	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
ELAM-1	NULL
by	NULL
stimulated	NULL
endothelium	NULL
,	NULL
the	NULL
results	NULL
suggest	NULL
that	NULL
glucocorticoids	NULL
act	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

Dexamethasone	NULL
Does	NULL
Not	NULL
Reverse	NULL
the	NULL
Effect	NULL
of	NULL
TNF-a	NULL
on	NULL
Endothelial	NULL
Adhesiveness	NULL
for	NULL
PMNs	NULL
.	NULL

Since	NULL
dexamethasone	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
level	NULL
of	NULL
message	NULL
for	NULL
ELAM-1	NULL
in	NULL
TNF-a-stimulated	NULL
HUVECs	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
this	NULL
was	NULL
reflected	NULL
in	NULL
the	NULL
adhesiveness	NULL
of	NULL
TNF-a-treated	NULL
endothelium	NULL
for	NULL
PMNs	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
,	NULL
TNF-a	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
9994	NULL
Medical	NULL
Sciences	NULL
:	NULL
Cronstein	NULL
et	NULL
al	NULL
.	NULL

100	NULL
75	NULL
50	NULL
25	NULL
125	NULL
EL	NULL
AM	NULL
100	NULL
75	NULL
%	NULL
CONTROL	NULL
INCREMENT	NULL
(	NULL
RFU	NULL
)	NULL
50	NULL
25	NULL
CONTROL	NULL
RU-486	NULL
DEX	NULL
RU-486+DEX	NULL
HCT	NULL
THF	NULL
SAL	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Corticosteroids	NULL
inhibit	NULL
the	NULL
LPS-stimulated	NULL
expression	NULL
of	NULL
ICAM-1	NULL
and	NULL
ELAM-1	NULL
.	NULL

HUVECs	NULL
were	NULL
incubated	NULL
with	NULL
LPS	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
(	NULL
DEX	NULL
,	NULL
100	NULL
nM	NULL
)	NULL
,	NULL
RU-486	NULL
(	NULL
10	NULL
1M	NULL
)	NULL
,	NULL
dexamethasone	NULL
plus	NULL
RU-486	NULL
,	NULL
cortisol	NULL
(	NULL
HCT	NULL
,	NULL
10	NULL
M	NULL
)	NULL
,	NULL
tetrahydrocortisol	NULL
(	NULL
THF	NULL
,	NULL
10	NULL
uM	NULL
)	NULL
,	NULL
or	NULL
sodium	NULL
salicylate	NULL
(	NULL
SAL	NULL
,	NULL
1.25	NULL
mM	NULL
)	NULL
.	NULL

(	NULL
Upper	NULL
)	NULL
Effect	NULL
of	NULL
the	NULL
various	NULL
compounds	NULL
tested	NULL
on	NULL
the	NULL
LPS-induced	NULL
increment	NULL
in	NULL
expression	NULL
of	NULL
ICAM-1	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
increment	NULL
induced	NULL
by	NULL
LPS	NULL
alone	NULL
.	NULL

(	NULL
Lower	NULL
)	NULL
Effect	NULL
of	NULL
these	NULL
same	NULL
compounds	NULL
on	NULL
the	NULL
LPS-stimulated	NULL
increment	NULL
in	NULL
ELAM-1	NULL
expres-sion	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
3-10	NULL
experiments	NULL
.	NULL

RFU	NULL
,	NULL
relative	NULL
fluorescence	NULL
units	NULL
.	NULL

rendered	NULL
the	NULL
endothelium	NULL
more	NULL
adhesive	NULL
to	NULL
PMNs	NULL
(	NULL
23	NULL
%	NULL
+	NULL
1	NULL
%	NULL
adherence	NULL
vs.	NULL
9	NULL
%	NULL
+	NULL
2	NULL
%	NULL
adherence	NULL
,	NULL
n	NULL
=	NULL
4	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
and	NULL
dexamethasone	NULL
did	NULL
not	NULL
diminish	NULL
the	NULL
increased	NULL
adhesiveness	NULL
of	NULL
TNF-stimulated	NULL
endothelium	NULL
for	NULL
PMNs	NULL
(	NULL
21	NULL
%	NULL
+	NULL
1	NULL
%	NULL
adherence	NULL
,	NULL
n	NULL
=	NULL
4	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
show	NULL
here	NULL
that	NULL
one	NULL
important	NULL
mechanism	NULL
by	NULL
which	NULL
glucocorticoids	NULL
may	NULL
affect	NULL
the	NULL
inflammatory	NULL
response	NULL
is	NULL
modulation	NULL
of	NULL
the	NULL
capacity	NULL
of	NULL
the	NULL
endothelium	NULL
to	NULL
respond	NULL
to	NULL
an	NULL
inflammatory	NULL
stimulus	NULL
.	NULL

Glucocorticoids	NULL
,	NULL
acting	NULL
at	NULL
their	NULL
cytoplasmic	NULL
receptors	NULL
,	NULL
diminish	NULL
the	NULL
LPS-stimulated	NULL
increase	NULL
in	NULL
endothelial	NULL
adhesiveness	NULL
for	NULL
resting	NULL
PMNs	NULL
and	NULL
diminish	NULL
transcription	NULL
and	NULL
expression	NULL
of	NULL
pro-inflammatory	NULL
adhesive	NULL
molecules	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
endothelium	NULL
.	NULL

Since	NULL
recent	NULL
studies	NULL
have	NULL
increasingly	NULL
pointed	NULL
to	NULL
the	NULL
central	NULL
role	NULL
of	NULL
the	NULL
endothelium	NULL
in	NULL
directing	NULL
the	NULL
traffic	NULL
of	NULL
leukocytes	NULL
into	NULL
inflamed	NULL
areas	NULL
,	NULL
our	NULL
observations	NULL
bear	NULL
directly	NULL
on	NULL
the	NULL
mechanism	NULL
for	NULL
the	NULL
antiinflammatory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
.	NULL

Moreover	NULL
,	NULL
our	NULL
results	NULL
help	NULL
to	NULL
explain	NULL
the	NULL
dramatic	NULL
leukocy-tosis	NULL
observed	NULL
in	NULL
patients	NULL
taking	NULL
therapeutic	NULL
doses	NULL
of	NULL
corticosteroids	NULL
[	NULL
concentrations	NULL
similar	NULL
to	NULL
those	NULL
studied	NULL
here	NULL
(	NULL
17	NULL
)	NULL
]	NULL
.	NULL

RU-486	NULL
stabilizes	NULL
the	NULL
association	NULL
of	NULL
steroid	NULL
receptors	NULL
with	NULL
heat	NULL
shock	NULL
protein	NULL
90	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ligand	NULL
,	NULL
which	NULL
prevents	NULL
translocation	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
thereby	NULL
blocks	NULL
transcription	NULL
of	NULL
genes	NULL
containing	NULL
glucocorticoid-responsive	NULL
elements	NULL
(	NULL
33	NULL
,	NULL
35-40	NULL
)	NULL
.	NULL

Our	NULL
demonstration	NULL
that	NULL
RU-486	NULL
reverses	NULL
the	NULL
effects	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
adhesive	NULL
qualities	NULL
of	NULL
HUVECs	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
adhesive	NULL
molecules	NULL
on	NULL
their	NULL
surface	NULL
is	NULL
therefore	NULL
most	NULL
consistent	NULL
with	NULL
the	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
IL-1	NULL
DEX	NULL
<	NULL
<	NULL
ELAM	NULL
<	NULL
ACTIN	NULL
<	NULL
ELAM	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Dexamethasone	NULL
inhibits	NULL
the	NULL
stimulated	NULL
increase	NULL
in	NULL
mRNA	NULL
for	NULL
ELAM	NULL
.	NULL

(	NULL
4	NULL
)	NULL
HUVECs	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
-	NULL
)	NULL
or	NULL
with	NULL
(	NULL
+	NULL
)	NULL
LPS	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
and	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
dexamethasone	NULL
(	NULL
DEX	NULL
,	NULL
0.1	NULL
uM	NULL
)	NULL
.	NULL

When	NULL
normalized	NULL
for	NULL
the	NULL
content	NULL
of	NULL
actin	NULL
mRNA	NULL
,	NULL
LPS	NULL
stimulated	NULL
a	NULL
234	NULL
%	NULL
increase	NULL
in	NULL
mRNA	NULL
for	NULL
ELAM	NULL
.	NULL

Dexamethasone	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
(	NULL
98	NULL
%	NULL
of	NULL
control	NULL
)	NULL
but	NULL
completely	NULL
inhibited	NULL
the	NULL
LPS-stimulated	NULL
increase	NULL
in	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
(	NULL
90	NULL
%	NULL
inhibition	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
found	NULL
in	NULL
a	NULL
second	NULL
experiment	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HUVECs	NULL
were	NULL
incubated	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
IL-la	NULL
(	NULL
20	NULL
units/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
.	NULL

When	NULL
normalized	NULL
to	NULL
the	NULL
content	NULL
of	NULL
actin	NULL
mRNA	NULL
,	NULL
dexamethasone	NULL
inhibited	NULL
the	NULL
IL-la-induced	NULL
increase	NULL
in	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
by	NULL
95	NULL
%	NULL
without	NULL
affecting	NULL
basal	NULL
levels	NULL
of	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
(	NULL
104	NULL
%	NULL
of	NULL
control	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
found	NULL
in	NULL
a	NULL
second	NULL
experiment	NULL
.	NULL

(	NULL
C	NULL
)	NULL
HUVECs	NULL
were	NULL
incubated	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
TNF-a	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
.	NULL

When	NULL
normalized	NULL
to	NULL
the	NULL
content	NULL
of	NULL
actin	NULL
mRNA	NULL
,	NULL
dexamethasone	NULL
did	NULL
not	NULL
affect	NULL
either	NULL
basal	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
(	NULL
97	NULL
%	NULL
of	NULL
control	NULL
)	NULL
or	NULL
the	NULL
TNF-a-induced	NULL
increment	NULL
in	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
(	NULL
110	NULL
%	NULL
of	NULL
control	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
found	NULL
in	NULL
a	NULL
second	NULL
experiment	NULL
.	NULL

hypothesis	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
steroids	NULL
on	NULL
the	NULL
endothelium	NULL
are	NULL
mediated	NULL
through	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Further	NULL
confirmation	NULL
is	NULL
provided	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
cortisol	NULL
,	NULL
but	NULL
not	NULL
its	NULL
inactive	NULL
metabolite	NULL
tetrahydrocortisol	NULL
,	NULL
inhibits	NULL
endothelial	NULL
cell	NULL
responses	NULL
to	NULL
LPS	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
a	NULL
glucocorticoid-responsive	NULL
element	NULL
in	NULL
the	NULL
gene	NULL
for	NULL
EL	NULL
AM-1	NULL
suggests	NULL
that	NULL
glucocorticoids	NULL
must	NULL
either	NULL
interfere	NULL
directly	NULL
with	NULL
a	NULL
transcriptional	NULL
regulator	NULL
of	NULL
ELAM-1	NULL
transcription	NULL
or	NULL
induce	NULL
the	NULL
synthesis	NULL
of	NULL
a	NULL
second	NULL
regulatory	NULL
element	NULL
.	NULL

Montgomery	NULL
and	NULL
co-workers	NULL
(	NULL
41	NULL
)	NULL
have	NULL
demonstrated	NULL
that	NULL
NFKB	NULL
regulatory	NULL
elements	NULL
are	NULL
necessary	NULL
(	NULL
but	NULL
not	NULL
sufficient	NULL
)	NULL
for	NULL
transcription	NULL
of	NULL
ELAM-1	NULL
.	NULL

Thus	NULL
the	NULL
induction	NULL
by	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
hGR	NULL
)	NULL
of	NULL
the	NULL
synthesis	NULL
of	NULL
a	NULL
counterregulatory	NULL
element	NULL
such	NULL
as	NULL
IB	NULL
could	NULL
Medical	NULL
Sciences	NULL
:	NULL
Cronstein	NULL
et	NULL
al	NULL
.	NULL

account	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
ELAM-1	NULL
expression	NULL
by	NULL
dexa-methasone	NULL
.	NULL

Steroid-receptor	NULL
complexes	NULL
also	NULL
participate	NULL
in	NULL
protein-protein	NULL
interactions	NULL
with	NULL
jun	NULL
,	NULL
preventing	NULL
its	NULL
interaction	NULL
at	NULL
AP-1	NULL
regulatory	NULL
sites	NULL
of	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
regions	NULL
of	NULL
appropriate	NULL
genes	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
although	NULL
the	NULL
AP-1	NULL
site	NULL
present	NULL
in	NULL
the	NULL
gene	NULL
for	NULL
ELAM-1	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
ELAM-1	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
appear	NULL
to	NULL
differ	NULL
from	NULL
those	NULL
of	NULL
Bochner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
5	NULL
)	NULL
,	NULL
who	NULL
found	NULL
that	NULL
prolonged	NULL
(	NULL
24	NULL
hr	NULL
)	NULL
treatment	NULL
of	NULL
microvascular	NULL
endothelium	NULL
from	NULL
foreskin	NULL
with	NULL
glucocorticoids	NULL
did	NULL
not	NULL
prevent	NULL
LPS	NULL
from	NULL
modulating	NULL
PMN	NULL
adhesion	NULL
,	NULL
whereas	NULL
,	NULL
as	NULL
we	NULL
report	NULL
here	NULL
,	NULL
treatment	NULL
of	NULL
HUVECs	NULL
for	NULL
4	NULL
hr	NULL
dramatically	NULL
diminished	NULL
adhesiveness	NULL
.	NULL

The	NULL
inefficacy	NULL
of	NULL
prolonged	NULL
treatment	NULL
with	NULL
corticosteroids	NULL
may	NULL
have	NULL
been	NULL
due	NULL
to	NULL
``	NULL
desensiti-zation	NULL
``	NULL
of	NULL
hGR	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
complete	NULL
depletion	NULL
of	NULL
hGR	NULL
in	NULL
the	NULL
cytosol	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
high	NULL
concentrations	NULL
of	NULL
agonist	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
occupancy	NULL
of	NULL
hGR	NULL
may	NULL
only	NULL
transiently	NULL
transactivate	NULL
genes	NULL
that	NULL
regulate	NULL
ELAM-1	NULL
transcription	NULL
or	NULL
translation	NULL
,	NULL
permitting	NULL
subsequent	NULL
activation	NULL
of	NULL
ELAM-1	NULL
transcription	NULL
by	NULL
LPS	NULL
.	NULL

We	NULL
were	NULL
surprised	NULL
to	NULL
observe	NULL
that	NULL
dexamethasone	NULL
did	NULL
not	NULL
inhibit	NULL
accumulation	NULL
of	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
induced	NULL
by	NULL
TNF-a	NULL
.	NULL

In	NULL
parallel	NULL
studies	NULL
Ghezzi	NULL
and	NULL
Sipe	NULL
(	NULL
43	NULL
)	NULL
found	NULL
that	NULL
dexamethasone	NULL
inhibited	NULL
LPS-stimulated	NULL
,	NULL
but	NULL
not	NULL
TNF-	NULL
or	NULL
IL-1-stimulated	NULL
,	NULL
serum	NULL
amyloid	NULL
protein	NULL
A	NULL
secretion	NULL
in	NULL
mice	NULL
.	NULL

Thus	NULL
LPS	NULL
,	NULL
TNF	NULL
,	NULL
and	NULL
IL-1	NULL
may	NULL
induce	NULL
the	NULL
transcription	NULL
of	NULL
ELAM-1	NULL
by	NULL
several	NULL
different	NULL
mechanisms	NULL
,	NULL
only	NULL
some	NULL
of	NULL
which	NULL
are	NULL
sensitive	NULL
to	NULL
corticosteroids	NULL
.	NULL

These	NULL
experiments	NULL
permit	NULL
us	NULL
to	NULL
suggest	NULL
a	NULL
mechanism	NULL
for	NULL
the	NULL
antiinflammatory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
:	NULL
acting	NULL
via	NULL
their	NULL
receptor	NULL
,	NULL
glucocorticoids	NULL
prevent	NULL
the	NULL
recruitment	NULL
of	NULL
leukocytes	NULL
at	NULL
inflammatory	NULL
loci	NULL
by	NULL
inhibiting	NULL
the	NULL
display	NULL
of	NULL
adhesive	NULL
molecules	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
endothelium	NULL
.	NULL

This	NULL
hypothesis	NULL
rests	NULL
on	NULL
three	NULL
separate	NULL
lines	NULL
of	NULL
evidence	NULL
:	NULL
functional	NULL
,	NULL
at	NULL
nanomolar	NULL
concentrations	NULL
glucocorticoids	NULL
inhibit	NULL
endotoxin-stimulated	NULL
increases	NULL
of	NULL
endothelial	NULL
adhesiveness	NULL
for	NULL
leuko-cytes	NULL
;	NULL
phenotypic	NULL
,	NULL
at	NULL
similar	NULL
concentrations	NULL
they	NULL
inhibit	NULL
the	NULL
stimulated	NULL
expression	NULL
of	NULL
adhesive	NULL
molecules	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
HUVECs	NULL
;	NULL
genotypic	NULL
,	NULL
glucocorticoids	NULL
inhibit	NULL
accumulation	NULL
of	NULL
mRNA	NULL
for	NULL
ELAM-1	NULL
in	NULL
endotoxin-	NULL
and	NULL
IL-1-stimulated	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
direct	NULL
receptor-mediated	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
the	NULL
capacity	NULL
of	NULL
HUVECs	NULL
to	NULL
localize	NULL
the	NULL
inflammatory	NULL
response	NULL
,	NULL
glucocorticoids	NULL
also	NULL
inhibit	NULL
the	NULL
ligand-induced	NULL
release	NULL
of	NULL
cytokines	NULL
(	NULL
IL-1	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
TNF-a	NULL
)	NULL
by	NULL
endothelial	NULL
and	NULL
other	NULL
inflammatory	NULL
cells	NULL
(	NULL
5-12	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
the	NULL
general	NULL
hypothesis	NULL
that	NULL
corticosteroids	NULL
act	NULL
as	NULL
antiinflammatory	NULL
agents	NULL
by	NULL
diminishing	NULL
,	NULL
directly	NULL
and	NULL
indi-rectly	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
HUVECs	NULL
to	NULL
direct	NULL
leukocyte	NULL
traffic	NULL
into	NULL
inflamed	NULL
or	NULL
infected	NULL
tissue	NULL
.	NULL

Our	NULL
data	NULL
also	NULL
provide	NULL
a	NULL
reasonable	NULL
explanation	NULL
for	NULL
the	NULL
opposing	NULL
effects	NULL
of	NULL
endotoxin	NULL
and	NULL
glucocorticoids	NULL
in	NULL
infection	NULL
and	NULL
immunity	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Herbert	NULL
Samuels	NULL
for	NULL
his	NULL
critical	NULL
suggestions	NULL
,	NULL
Dr.	NULL
Michael	NULL
Bevilacqua	NULL
for	NULL
his	NULL
gift	NULL
of	NULL
antibody	NULL
H18/7	NULL
,	NULL
and	NULL
Dr.	NULL
Tucker	NULL
Collins	NULL
for	NULL
generously	NULL
providing	NULL
a	NULL
cDNA	NULL
probe	NULL
for	NULL
ELAM-1	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dwight	NULL
Naime	NULL
,	NULL
Phoebe	NULL
Recht	NULL
,	NULL
and	NULL
Clara	NULL
Ekundayo	NULL
for	NULL
their	NULL
technical	NULL
assistance	NULL
.	NULL

B.N.C	NULL
.	NULL

and	NULL
S.C.K	NULL
.	NULL

contributed	NULL
to	NULL
this	NULL
work	NULL
equally	NULL
.	NULL

These	NULL
studies	NULL
were	NULL
performed	NULL
during	NULL
B.N.C	NULL
.	NULL

's	NULL
tenure	NULL
as	NULL
the	NULL
Irene	NULL
Duggan	NULL
Arthritis	NULL
Investigator	NULL
of	NULL
the	NULL
Arthritis	NULL
Founda-tion	NULL
.	NULL

This	NULL
research	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
support	NULL
of	NULL
grants	NULL
from	NULL
the	NULL
American	NULL
Heart	NULL
Association	NULL
(	NULL
New	NULL
York	NULL
Affiliate	NULL
)	NULL
to	NULL
B.N.C	NULL
.	NULL

and	NULL
R.I.L	NULL
.	NULL

,	NULL
the	NULL
Arthritis	NULL
Foundation	NULL
(	NULL
New	NULL
York	NULL
Chapter	NULL
)	NULL
to	NULL
B.N.C	NULL
.	NULL

,	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
AR	NULL
11949	NULL
,	NULL
HL	NULL
19721	NULL
)	NULL
to	NULL
G.W	NULL
.	NULL

,	NULL
the	NULL
Evans	NULL
Foundation	NULL
,	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Aaron	NULL
Diamond	NULL
Foundation	NULL
under	NULL
the	NULL
Clinical	NULL
Scientist	NULL
Program	NULL
to	NULL
R.LL	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Samuels	NULL
,	NULL
H.	NULL
H.	NULL
&	NULL
Tomkins	NULL
,	NULL
G.	NULL
M.	NULL
(	NULL
1970	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

52	NULL
,	NULL
57-74	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Parillo	NULL
,	NULL
J.	NULL
E.	NULL
&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1979	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Pharmacol	NULL
.	NULL

Toxicol	NULL
.	NULL

19	NULL
,	NULL
179-201	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Blackwell	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Flower	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Nijkamp	NULL
,	NULL
F.	NULL
P.	NULL
&	NULL
Vane	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1978	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

62	NULL
,	NULL
79-89	NULL
.	NULL

4	NULL
.	NULL

Flower	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Agents	NULL
Actions	NULL
17	NULL
,	NULL
255-262	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

21	NULL
.	NULL

DBE	NULL
}	NULL
BN	NULL
R	NULL
S3	NULL
32	NULL
.	NULL

33	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41.	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
(	NULL
1992	NULL
)	NULL
9995	NULL
Bochner	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
Rutledge	NULL
,	NULL
B.	NULL
K.	NULL
&	NULL
Schleimer	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

139	NULL
,	NULL
2303-2307	NULL
.	NULL

Djaldetti	NULL
,	NULL
R.	NULL
,	NULL
Fishman	NULL
,	NULL
P.	NULL
,	NULL
Shtatlender	NULL
,	NULL
V.	NULL
,	NULL
Sredni	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Djaldetti	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Biomed	NULL
.	NULL

Pharmacother	NULL
.	NULL

44	NULL
,	NULL
515-518	NULL
.	NULL

Kirnbauer	NULL
,	NULL
R.	NULL
,	NULL
Kock	NULL
,	NULL
A.	NULL
,	NULL
Neuner	NULL
,	NULL
P.	NULL
,	NULL
Forster	NULL
,	NULL
E.	NULL
,	NULL
Koutmann	NULL
,	NULL
J.	NULL
,	NULL
Urbanski	NULL
,	NULL
A.	NULL
,	NULL
Schauer	NULL
,	NULL
E.	NULL
,	NULL
Ansel	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Schwarz	NULL
,	NULL
T.	NULL
&	NULL
Luger	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

96	NULL
,	NULL
484-489	NULL
.	NULL

Chensue	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Terebuh	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Remick	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Scales	NULL
,	NULL
W.	NULL
E.	NULL
&	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

138	NULL
,	NULL
395-402	NULL
.	NULL

Zuckerman	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Shellhaas	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Butler	NULL
,	NULL
L.	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

19	NULL
,	NULL
301-305	NULL
.	NULL

Knudsen	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Strom	NULL
,	NULL
T.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

139	NULL
,	NULL
4129-4134	NULL
.	NULL

Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Mier	NULL
,	NULL
J.	NULL
W.	NULL
(	NULL
1987	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

317	NULL
,	NULL
940-945	NULL
.	NULL

Beutler	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Cerami	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
625-655	NULL
.	NULL

Shapiro	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Campbell	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Kobayashi	NULL
,	NULL
D.	NULL
K.	NULL
&	NULL
Welgus	NULL
,	NULL
H.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

146	NULL
,	NULL
2724-2729	NULL
.	NULL

Clark	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Kobayashi	NULL
,	NULL
D.	NULL
K.	NULL
&	NULL
Welgus	NULL
,	NULL
H.	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

80	NULL
,	NULL
1280-1288	NULL
.	NULL

Weissmann	NULL
,	NULL
G.	NULL
&	NULL
Thomas	NULL
,	NULL
L.	NULL
(	NULL
1963	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

42	NULL
,	NULL
661-669	NULL
.	NULL

Bangham	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Standish	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Weissmann	NULL
,	NULL
G.	NULL
(	NULL
1965	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
253-259	NULL
.	NULL

Athens	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Haab	NULL
,	NULL
O.	NULL
P.	NULL
,	NULL
Raab	NULL
,	NULL
S.	NULL
O.	NULL
,	NULL
Mauer	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Ashen-brucker	NULL
,	NULL
H.	NULL
,	NULL
Cartwright	NULL
,	NULL
G.	NULL
E.	NULL
&	NULL
Wintrobe	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
1961	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

40	NULL
,	NULL
989-995	NULL
.	NULL

Selye	NULL
,	NULL
H.	NULL
(	NULL
1953	NULL
)	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Med	NULL
.	NULL

Assoc	NULL
.	NULL

152	NULL
,	NULL
1207-1213	NULL
.	NULL

Zweiman	NULL
,	NULL
B.	NULL
,	NULL
Slott	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

&	NULL
Atkins	NULL
,	NULL
P.	NULL
C.	NULL
(	NULL
1976	NULL
)	NULL
J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

58	NULL
,	NULL
657-663	NULL
.	NULL

Bevilacqua	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Mendrick	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Cotran	NULL
,	NULL
R.	NULL
S.	NULL
&	NULL
Gimbrone	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
$	NULL
4	NULL
,	NULL
9238-9242	NULL
.	NULL

Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Lapierre	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Stolpen	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Brock	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Springer	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Fiers	NULL
,	NULL
W.	NULL
,	NULL
Bevilacqua	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
Mendrick	NULL
,	NULL
D.	NULL
L.	NULL
&	NULL
Gimbrone	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

138	NULL
,	NULL
3319-3324	NULL
.	NULL

Walz	NULL
,	NULL
G.	NULL
,	NULL
Aruffo	NULL
,	NULL
A.	NULL
,	NULL
Kolanus	NULL
,	NULL
W.	NULL
,	NULL
Bevilacqua	NULL
,	NULL
M.	NULL
&	NULL
Seed	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
250	NULL
,	NULL
1132-1135	NULL
.	NULL

Geng	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Bevilacqua	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Moore	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Mcintyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Kim	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Bliss	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

&	NULL
McEver	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
343	NULL
,	NULL
757-760	NULL
.	NULL

Larson	NULL
,	NULL
R.	NULL
S.	NULL
&	NULL
Springer	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

114	NULL
,	NULL
181-217	NULL
.	NULL

Smith	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
Kishimoto	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Abbass	NULL
,	NULL
O.	NULL
,	NULL
Hughes	NULL
,	NULL
B.	NULL
,	NULL
Rothlein	NULL
,	NULL
R.	NULL
,	NULL
McIntire	NULL
,	NULL
L.	NULL
V.	NULL
,	NULL
Butcher	NULL
,	NULL
E.	NULL
&	NULL
Anderson	NULL
,	NULL
D.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

81	NULL
,	NULL
609-618	NULL
.	NULL

Jaffe	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Nachman	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Becker	NULL
,	NULL
C.	NULL
G.	NULL
&	NULL
Minick	NULL
,	NULL
C.	NULL
R.	NULL
(	NULL
1973	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

52	NULL
,	NULL
2745-2756	NULL
.	NULL

Boyum	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1968	NULL
)	NULL
Scand	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

21	NULL
,	NULL
Suppl	NULL
.	NULL

97	NULL
,	NULL
77-98	NULL
.	NULL

Cronstein	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
Eberle	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Gruber	NULL
,	NULL
H.	NULL
E.	NULL
&	NULL
Levin	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
2441-2445	NULL
.	NULL

Cronstein	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
Levin	NULL
,	NULL
R.	NULL
I.	NULL
,	NULL
Philips	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Hirschhorn	NULL
,	NULL
R.	NULL
,	NULL
Abramson	NULL
,	NULL
S.	NULL
B	NULL
.	NULL

&	NULL
Weissmann	NULL
,	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
2201-2206	NULL
.	NULL

Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Bevilacqua	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Mendrick	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Lapierre	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Fiers	NULL
,	NULL
W.	NULL
&	NULL
Gimbrone	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
Jr.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

136	NULL
,	NULL
1680-1687	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
2nd	NULL
Ed	NULL
.	NULL

Pohiman	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Stanness	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Beatty	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Ochs	NULL
,	NULL
H.	NULL
D.	NULL
&	NULL
Harlan	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

136	NULL
,	NULL
4548-4553	NULL
.	NULL

Groyer	NULL
,	NULL
A.	NULL
,	NULL
Schweizer-Groyer	NULL
,	NULL
G.	NULL
,	NULL
Cadepond	NULL
,	NULL
F.	NULL
,	NULL
Mavuller	NULL
,	NULL
M.	NULL
&	NULL
Beaulieu	NULL
,	NULL
E.	NULL
E.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
328	NULL
,	NULL
624-626	NULL
.	NULL

Beaulieu	NULL
,	NULL
E.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
245	NULL
,	NULL
1351-1357	NULL
.	NULL

Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
240	NULL
,	NULL
889-895	NULL
.	NULL

Yang	NULL
Yen	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
Chambard	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Sun	NULL
,	NULL
Y.	NULL
L.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Drovin	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1205-1215	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
Rangarajan	NULL
,	NULL
P.	NULL
,	NULL
Kliewer	NULL
,	NULL
S.	NULL
,	NULL
Ransone	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Bolado	NULL
,	NULL
J.	NULL
,	NULL
Yang	NULL
,	NULL
N.	NULL
,	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1217-1226	NULL
.	NULL

Cadepond	NULL
,	NULL
F.	NULL
,	NULL
Schweizer-Groyer	NULL
,	NULL
G.	NULL
,	NULL
Segard-Maurel	NULL
,	NULL
L.	NULL
,	NULL
Jibard	NULL
,	NULL
N.	NULL
,	NULL
Hollenberg	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Giguere	NULL
,	NULL
V.	NULL
,	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Beaulieu	NULL
,	NULL
E.	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

266	NULL
,	NULL
5834-5841	NULL
.	NULL

Picard	NULL
,	NULL
D.	NULL
,	NULL
Khursheed	NULL
,	NULL
B.	NULL
,	NULL
Garabedian	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Fortin	NULL
,	NULL
M.G	NULL
.	NULL

,	NULL
Lindquist	NULL
,	NULL
S.	NULL
&	NULL
Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
348	NULL
,	NULL
166-168	NULL
.	NULL

Dalman	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Scherre	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
Taylor	NULL
,	NULL
L.	NULL
P.	NULL
,	NULL
Akil	NULL
,	NULL
H.	NULL
&	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
3482-3490	NULL
.	NULL

Montgomery	NULL
,	NULL
K.	NULL
F.	NULL
,	NULL
Osborn	NULL
,	NULL
L.	NULL
,	NULL
Hession	NULL
,	NULL
C.	NULL
,	NULL
Tizard	NULL
,	NULL
R.	NULL
,	NULL
Goff	NULL
,	NULL
D.	NULL
,	NULL
Vassallo	NULL
,	NULL
C.	NULL
,	NULL
Tarr	NULL
,	NULL
P.	NULL
I.	NULL
,	NULL
Bomsztyk	NULL
,	NULL
K.	NULL
,	NULL
Cobb	NULL
,	NULL
R.	NULL
,	NULL
Harlan	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Pohlman	NULL
,	NULL
T.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
6523-6527	NULL
.	NULL

Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
(	NULL
1985	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Genet	NULL
.	NULL

19	NULL
,	NULL
209-252	NULL
.	NULL

Ghezzi	NULL
,	NULL
P.	NULL
&	NULL
Sipe	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Lymphokine	NULL
Res	NULL
.	NULL

7	NULL
,	NULL
157-166	NULL
.	NULL

